secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001682852-22-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q2 revenue $4.7B, GAAP EPS $5.24, announces $3B buyback, reiterates ~$21B 2022 sales outlook
--------------------------------------------------------------------------------

- Q2 revenue $4.7B vs $4.4B YoY; GAAP net income $2.2B ($5.24 diluted EPS) vs $2.8B ($6.46) YoY.
- Board authorizes new $3B share repurchase program; $1.9B used in H1 2022 repurchases.
- 2022 advance purchase agreements for COVID vaccine expected delivery ~$21B; Q4 sales seen > Q3.
- Cost of sales 30% of product sales in Q2, including $499M inventory write-downs and $184M purchase commitment loss.
- Four infectious disease vaccines in Phase 3; proof-of-concept data in rare diseases and immuno-oncology expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000040/0001682852-22-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000040/mrna-20220803.htm
  HTML page:      https://secwatch.observer/filing/0001682852-22-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer